Loading stock…

Merit Medical Systems, Inc. (MMSI) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Merit Medical Systems, Inc.

MMSIMarket cap $5.08BPrice $85.1

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes disposable devices for cardiology and radiology procedures—catheters, stents, and needles used in cath labs worldwide. Its products touch millions of patients yearly, yet most people have never heard the name behind the equipment.

In Bastion Portfolios?

52W Return+4%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+10%7

Revenue Forecast

Rev CAGR (1y)+8%5

Rev CAGR (3y)+7%5

Rev CAGR (5y)+6%6

Earnings Forecast

EPS Growth Y+1+101%10

EPS Growth Y+2+10%7

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin14%6

Net Income Margin9%5

Free Cash Flow Margin13%7

Debt

Net Debt/EBITDA1.06

Efficiency

ROE9%4

ROA5%6

Earnings Stability1010

GEAR+STRONG76

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)194

P/E Ratio (Forward 3y)164

P/BV3.05

EV Multiples

EV/EBITDA Fwd135

EV/EBIT Fwd165

Yield

Free Cash Flow Yield4.0%6

Dividend Yieldna–

Momentum

Short term

1 month return-3%6

3 month return+20%10

YTD return-3%4

Mid term

Price vs 52wHigh90%8

1 year return+2%5

Long term

3 year return+26%4

5 year return+17%4

Risk Shield

Price Risk

Beta0.67

Volatility30%7

Free Cash Flow

Free Cash Flow Margin13%7

Free Cash Flow Yield4.0%6

Quality

ROCE9%5

Earnings Stability1010

Net Debt/EBITDA1.06

02Growth

Is it actually growing, and how fast?

MMSIMerit Medical Systems

Revenue FY25$1.5B

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+6%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+101%10

EPS growth, FY27E+10%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 10%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 6%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE65 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+20%10

YTD return-3%4

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+2%5

3-year return+26%4

5-year return+17%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 2% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+20%).

WATCH

Average long-term results. Multi-year returns are middling (+26% over three years and +17% over five), roughly average for the market.

Returns sit at the market level over the past month (-3%) and so far this year (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Merit Medical Systems, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MMSIMerit Medical Systems

Revenue FY25$1.5B

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+6%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+101%10

EPS growth, FY27E+10%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 10%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 6%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE65 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+20%10

YTD return-3%4

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+2%5

3-year return+26%4

5-year return+17%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 2% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+20%).

WATCH

Average long-term results. Multi-year returns are middling (+26% over three years and +17% over five), roughly average for the market.

Returns sit at the market level over the past month (-3%) and so far this year (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Merit Medical Systems, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community